Check out today’s featured companies who have recently completed an M&A deal, and be sure to check out the full list of past healthcare IT M&A.
Anthropic Reportedly Acquires Medical AI Startup Coefficient Bio for $400M+
Anthropic PBC has reportedly acquired Coefficient Bio Inc., a provider of artificial intelligence software for medical researchers.
Half the startup’s stock was owned by a healthcare-focused venture capital firm called Dimension. The fund informed investors of the acquisition in a letter that was published today by journalist Eric Newcomer. According to the document, Anthropic is paying more than $400 million in stock for the company.
Coefficient was founded about eight months ago by a group of former pharmaceutical executives and researchers. According to Newcomer, the company developed AI models optimized for biology research. In a January post on X, one of the company’s co-founders stated that the company’s technology would “change everything about how the industry learns and makes decisions.” That hints that Coefficient’s models are built to automate particularly high-impact research tasks.
One of the most important medical research workflows to which startups are applying AI is small molecule discovery. Small molecules are biological building blocks about one nanometer in size that form the basis of most pharmaceuticals. Manas AI Inc., a startup active in that area, estimates AI can speed up certain aspects of the discovery workflow by a factor of 100.
One way researchers determine whether a small molecule has therapeutic applications is by checking its ability to dock to pathogens. If a small molecule can’t dock to a pathogen, it can’t neutralize it…
Full release here, originally announced April 3rd, 2026.
Qualifacts Acquires MethodOne to Fully Integrate Medication-Assisted Treatment into its EHR Platforms for Substance Use Disorder Providers
Acquisition Strengthens Qualifacts‘ Position as the Leading Behavioral Health EHR Provider, Enabling SUD and OTP Providers to Better Manage Controlled Medication Dispensing and Clinical Workflows in a Unified Solution
Qualifacts, the leading behavioral health technology partner specializing in AI-powered electronic health record (EHR) and data solutions, today announced the acquisition of MethodOne by Computalogic, a comprehensive controlled-medication dispensing software purpose-built for opioid treatment programs (OTPs) and substance use disorder (SUD) providers. The acquisition brings together Qualifacts’ award-winning EHR platforms with MethodOne’s best-in-class medication dispensing and inventory management capabilities, creating a single, fully integrated solution for the behavioral healthcare market.
The MethodOne integration expands Qualifacts’ EHR capabilities, closing a critical gap for SUD and complex mental health providers that increasingly require integrated medication-assisted treatment (MAT) and medications for opioid use disorder (MOUD) dispensing. There are approximately 2,224 OTPs operating in the United States, a segment that has grown at 5.6% CAGR since 2019 and collectively treats over half a billion patients annually, the majority of whom are Medicaid beneficiaries. Qualifacts’ existing customer feedback indicates that agencies are actively shifting from office-based opioid treatment (OBOT) models to OTPs to take advantage of simpler billing workflows, accelerating demand for an integrated platform that can support both clinical and dispensing needs.
“This acquisition is a direct response to what our customers are telling us they need,” said Josh Schoeller, CEO at Qualifacts. “Large SUD and mental health organizations require an integrated MAT and MOUD solution to operate effectively, and until now, that has meant cobbling together multiple systems. Bringing MethodOne into the Qualifacts family means our customers get a more complete behavioral healthcare EHR platform, with a single support relationship and a unified roadmap.”
OTP providers operate under some of the most demanding regulatory requirements in healthcare, subject to overlapping oversight from the DEA, SAMHSA, and state agencies. With MethodOne fully integrated into Qualifacts EHRs, organizations can significantly reduce compliance and billing burden by unifying clinical documentation and controlled substance dispensing workflows, while eliminating duplicative data entry and the risks that come with managing disconnected systems. Providers can spend less time managing software and more time delivering care.
MethodOne has built a strong reputation among SUD treatment providers for feature-rich functionality and ease of use. Its functionality is regarded as superior to existing alternatives in the market…
Full release here, originally announced April 7th, 2026.
No comments:
Post a Comment